Design of EGFR kinase inhibitors: A ligand-based approach and its confirmation with structure-based studies

被引:26
|
作者
Vema, A
Panigrahi, SK
Rambabu, G
Gopalakrishnan, B
Sarma, JARP
Desiraju, GR
机构
[1] TATA Consultancy Serv, Hyderabad 500001, Andhra Pradesh, India
[2] Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India
[3] gvk bioSci Pvt Ltd, Hyderabad 500016, Andhra Pradesh, India
关键词
D O I
10.1016/S0968-0896(03)00482-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Three-dimensional quantitative structure-activity relationship (3D-QSAR) models were developed for 100 anilinoquinazolines, inhibiting epidermal growth factor receptor (EGFR) kinase. The studies included molecular field analysis (MFA) and receptor surface analysis (RSA). The cross-validated r(2) (r(cv)(2)) values are 0.81 and 0.79 for MFA and RSA, respectively. The predictive ability of these models was validated by 28 test set molecules. The results of the best QSAR model were further compared with structure-based investigations using docking studies with the crystal structure of EGFR kinase domain. The results helped to understand the nature of substituents at the 6- and 7-positions, thereby providing new guidelines for the design of novel inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4643 / 4653
页数:11
相关论文
共 50 条
  • [1] Ligand-based and structure-based design of novel histone demethylase inhibitors
    Luca Carlino
    Martin Leo Schmitt
    Manfred Jung
    Wolfgang Sippl
    [J]. Journal of Cheminformatics, 5 (Suppl 1)
  • [2] Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach
    Lucas, Simon
    Heim, Ralf
    Negri, Matthias
    Antes, Iris
    Ries, Christina
    Schewe, Katarzyna E.
    Bisi, Alessandra
    Gobbi, Silvia
    Hartmann, Rolf W.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (19) : 6138 - 6149
  • [3] Progress in Structure-Based Design of EGFR Inhibitors
    Mitrasinovic, Petar M.
    [J]. CURRENT DRUG TARGETS, 2013, 14 (07) : 817 - 829
  • [4] Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors
    Shaikh, Gulam Moin
    Murahari, Manikanta
    Thakur, Shikha
    Kumar, Maushmi S.
    Mayur, Y. C.
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2022, 112
  • [5] Structure-Based and Ligand-Based Drug Design for HER 2 Receptor
    Huang, Hung-Jin
    Lee, Kuei-Jen
    Yu, Hsin Wei
    Chen, Chien-Yu
    Hsu, Chih-Ho
    Chen, Hsin-Yi
    Tsai, Fuu-Jen
    Chen, Calvin Yu-Chian
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2010, 28 (01): : 23 - 37
  • [6] Might template CoMFA integrate structure-based and ligand-based design?
    Cramer, Richard D.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [7] Integrating structure-based and ligand-based approaches for computational drug design
    Wilson, Gregory L.
    Lill, Markus A.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2011, 3 (06) : 735 - 750
  • [8] Identification of Mtb GlmU Uridyltransferase Domain Inhibitors by Ligand-Based and Structure-Based Drug Design Approaches
    Singh, Manvi
    Kempanna, Priya
    Bharatham, Kavitha
    [J]. MOLECULES, 2022, 27 (09):
  • [9] Structure-based and ligand-based drug design for microsomal prostaglandin E synthase-1 inhibitors
    Li, Chia-Ling
    Chang, Tung-Ti
    Sun, Mao-Feng
    Chen, Hsin-Yi
    Tsai, Fuu-Jen
    Fisher, Mark
    Chen, Calvin Yu-Chian
    Lee, Chun-Lin
    Fang, Wen-Chang
    Wong, Yung-Hao
    [J]. MOLECULAR SIMULATION, 2011, 37 (03) : 226 - 236
  • [10] Virtual screening workflow for glycogen synthase kinase 3β inhibitors: convergence of ligand-based and structure-based approaches
    VA Palyulin
    DI Osolodkin
    NS Zefirov
    [J]. Journal of Cheminformatics, 3 (Suppl 1)